Method for testing amyloid precursor protein in blood

Abstract

The invention discloses a method for testing amyloid precursor protein (APP) in blood. The method comprises the following steps of: firstly, phlebotomizing 2-3ml against the arm into a 1:9 aseptic sodium citrate anti-freezing tube; putting the tube into a refrigerator with the temperature of below 20 DEG C to store; taking 1ml blood when tested; centrifuging under 10000g for 3 minutes; carefully removing supernatant; keeping precipitates for later use; adding 120mu l of protein extracting liquid into cell precipitates to mix in a vortex mode; putting the cell precipitates on ice, standing for 20 minutes and centrifuging under 12000g for 3 minutes; taking supernatant; and performing Western blot experiment and observing a result. According to the invention, the method for identifying Alzheimer's disease (AD) or non-AD is easy, economic and reliable, convenient to detect and relatively easy to operate, and can rapidly obtain an experiment result; the experiment result is clear and easy to analyze; and the method is easy to take materials, the body cannot be wounded by only conventional arm phlebotomizing, the specificity and the sensitiveness of the method for identifying the AD and the non-AD are improved, and the research on new AD blood biomarkers is further developed.

Description

technical field [0001] The invention belongs to the technical field of protein measurement in blood, in particular to a method for measuring amyloid precursor protein (APP) in blood. Background technique [0002] A biomarker is an indicator of a biochemical process, which can be a biochemical change, a certain genetic characteristic, or a structural and functional change detected by imaging means. The information it provides is useful in disease prediction, early diagnosis , Prognosis judgment, drug efficacy evaluation, disease course monitoring and other aspects have important value. [0003] Utilizing the current AD biomarkers to detect AD usually causes certain damage to the body, there are many target markers to be detected, the operation is cumbersome, the specificity and sensitivity are not high enough, the cost is high, and the existing Biomarkers have not yet been able to identify those patients with underlying pathology who will develop AD. [0004] The Basic Clin...

AI Technical Summary

Problems solved by technology

A foreign laboratory has studied the expression of APP protein in platelets, but the platelet separation method is relatively cumbersome. Finally, the proportion of different APP subtypes needs to be compared, and the results are not very intuitive and reliable.

Another laboratory also analyzed the expression of APP protein in white blood cells in blood cells. The separation steps were also cumbersome, and the results were not intuitive and clear.

Images